BACE, a ␤-secretase, is an attractive potential disease-modifying therapeutic strategy for Alzheimer's disease (AD) as it results directly in the decrease of amyloid precursor protein (APP) processing through the ␤-secretase pathway and a lowering of CNS amyloid-␤ (A␤) levels. The interaction of the ␤-secretase and ␣-secretase pathway-mediated processing of APP in the rhesus monkey (nonhuman primate; NHP) CNS is not understood. We hypothesized that CNS inhibition of BACE would result in decreased newly generated A␤ and soluble APP␤ (sAPP␤), with increased newly generated sAPP␣.
Introduction
Amyloid precursor protein (APP) is a ubiquitous transmembrane protein involved in cell signaling, development, and gene regulation.
Compared with peripheral, non-CNS tissues, CNS APP processing demonstrates increased ␤-secretase (BACE) activity (Irizarry et al., 2001; Fukumoto et al., 2002) and different responses to ␥-secretase modulation . The differences between APP processing in the CNS and peripheral compartments are not fully understood (Ortega et al., 2013) ; further understanding of APP processing may be important to inform the design and development of Alzheimer's disease (AD) therapeutics.
APP is first cleaved by either BACE or ␣-secretase enzyme generating extracellular soluble APP-␤ (sAPP␤) or sAPP␣, respectively ( Fig. 1) . Following BACE cleavage, the APP C-terminal fragment C99 can be cleaved by ␥-secretase producing extracellular amyloid-␤ (A␤) and the remaining APP intracellular C-terminal domain. Recent reports Portelius et al., 2011) indicate there is an alternate pathway of a tandem ␣-secretase and BACE cleavage of APP, which results in APP metabolites such as A␤1-15/1-16. The relationship of physiological ␣-secretase to BACE processing in the CNS is not fully un-derstood, although some insights from inhibition studies of these enzymes suggest that APP can be shunted to other pathways (Mattsson et al., 2012) .
BACE inhibition has been proposed to decrease the amount of APP processed into A␤, and shunt APP to the ␣-secretase pathway. BACE1 appears to be the predominant BACE in the CNS and is located mainly in the membranes of cellular compartments. BACE1 may be increased ϳ2-fold in brains (Fukumoto et al., 2002; Li et al., 2004; Yang et al., 2003) or CSF of AD patients (Holsinger et al., 2006; Verheijen et al., 2006; , although recent reports suggest little change from healthy controls Rosén et al., 2012; . Brain penetrant BACE1 inhibitors capable of lowering CNS A␤ in rodent and nonhuman primate (NHP) models (Sankaranarayanan et al., 2009; Malamas et al., 2010; Takahashi et al., 2010; Truong et al., 2010; Mandal et al., 2012; Stamford et al., 2012) have been identified and multiple BACE inhibitors have advanced into early stages of human clinical trials (May et al., 2011; Egan et al., 2012 , Forman et al., 2013 Bernier et al., 2013) .
We sought to determine the kinetic behavior of APP metabolites and the relationship between the ␣-secretase and BACE pathways during BACE inhibition in rhesus macaques, an NHP model that has 91% homology of APP with human APP. We used stable isotope labeling kinetics (SILK) in combination with a novel high-affinity, selective, and centrally active BACE inhibitor to monitor the production and turnover of APP metabolites. By distinguishing the newly generated metabolites in the CSF from those that previously existed, SILK has provided a more sensitive determination of minute changes in APP metabolites in sporadic and autosomal dominant AD (Mawuenyega et al., 2010; Potter et al., 2013) . In the context of ␥-secretase inhibition, SILK demonstrated low-dose ␥-secretase inhibition effects on A␤ production ).
Materials and Methods

Cisterna magna ported conscious NHP model.
Animal use procedures in this study were reviewed and approved by the Institutional Animal Care and Use Committee at Merck Research Laboratories. They conform to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Research Council, 1996) . The cisterna magna ported (CMP) stable catheterization procedures and CSF flow and collection, as well as the vascular access port infusion protocol, were as described previously (Gilberto et al., 2003; .
13 C 6 -leucine infusion protocol and sample collection. At 48 h before administration of compound or vehicle, monkeys were restricted to a protein-free diet consisting of fruits and vegetables. Protein was reintroduced after the 12 h time point of the study (13 h post dosing of the BACE inhibitor).
13 C 6 -leucine infusion procedures were described previously . Briefly, a 4 mg/kg [U-13 C 6 ] leucine priming dose was administered intravenously for 10 min, followed by a steady infusion of 4 mg/kg/h for 12 h. Baseline CSF and blood samples were collected at Ϫ22, Ϫ20, and Ϫ1 h before primed leucine administration. CSF and blood samples were collected at 2, 4, 6, 8, 12, 15, 18, 21, 24, 27, 30, 48, 54, 57, 72 , and 144 h after the start of tracer leucine administration. At each time point, a total of 1.5 ml CSF was collected into low-binding polypropylene tubes (Axygen Scientific). The blood was collected into K2 EDTA Vacutainer tubes (Becton Dickinson), spun, and 800 l of plasma was collected. CSF and plasma samples were then separated into aliquots of lesser volume (into Axygen or standard polypropylene tubes) and placed immediately on dry ice, then stored in a Ϫ70°C freezer until analysis.
BACE inhibitor study protocol. The Merck BACE inhibitor, MBI-5 (see Table 1 for pharmacological profile), was used in a four-way crossover randomized design administering one of three doses. Vehicle (0.4% methylcellulose), or 10, 30, and 125 mg/kg MBI-5 was administered orally to conscious CMP NHP (n ϭ 5 male rhesus monkeys, 10 -13 years old, 8 -15 kg) 1 h before initiating the tracer leucine administration. CSF and plasma samples were collected as described above to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of this compound by quantifying MBI-5 concentrations (in plasma and CSF); absolute CSF concentrations of sAPP␣, sAPP␤, A␤ 1-40 , and A␤ 1-42 (as measured by ELISA); or 13 C 6 -leucine/ 12 C 6 -leucine-labeled CSF sAPP␣, sAPP␤, and total A␤; and free 13 C 6 -leucine/ 12 C 6 -leucine enrichment in plasma. Vehicle/BACE inhibitor administration and sample collection took place at Merck Research Laboratories. Subsequent PK analyses and CSF ELISA measurements also took place at Merck, whereas CSF and plasma were shipped on dry ice to Washington University for SILK analyses: all serial immunoprecipitation (IP)/mass spectrometry (MS) analyses, as well as analyses of total leucine enrichment. Cell culture to generate APP standards for SILK also took place at Washington University.
Cell culture to generate 13 C 6 -leucine/ 12 C 6 -leucine APP fragment standards. Human H4 neuroglioma cells stably transfected with human APP 751 (H4-APP wt ; courtesy of T. E. Golde, University of Florida, Gainesville) were grown in DMEM (Sigma-Aldrich) for two passages. Leucine-free DMEM (Sigma-Aldrich) was supplemented with a mixture of 13 C 6 -leucine ϩ 12 C 6 -leucine to generate final media solutions with a range of 0%, 1.25%, 2.5%, 5%, 10%, or 20% 13 C 6 -leucine. Total leucine concentrations across the mixtures were identical to standard DMEM (105 mg/L). DMEM solutions were supplemented with 1:50 B-27 and 1% each of penicillin-streptomycin and Zeocin. At the third passage, cells were pooled and split evenly at ϳ80% confluency in T-75 flasks. The (KLVFFAEDVGSN) is located in the middle of the A␤ sequence. We hypothesize that APP that remains uncleaved by ␤-secretase due to the presence of a BACE inhibitor will be available for cleavage by ␣-secretase.
H4-APP wt cells were reconstituted in one of the six prepared media solutions and cultured for 24 h to allow for sufficient incorporation of label into proteins. Following this incubation with labeled DMEM, the media solutions were collected and apportioned into Axygen tubes in 1 ml aliquots and immediately frozen and stored at Ϫ80°C until ready to use.
A␤, sAPP␤, and sAPP␣ ELISA protocols. The assays for CSF A␤ 1-40 , A␤ 1-42 , sAPP␣, and sAPP␤ measurement were described previously (Sankaranarayanan et al., 2009; Wu et al., 2011) with some modification in dilution factor. Briefly, CSF was diluted with 3% BSA/PBS at 1:3 for A␤ 1-42 , 1:10 for A␤ 1-40 , and 1:80 for both sAPP␤ and sAPP␣ and used at 100 l per ELISA well for each analyte measurement. The concentration was calculated based on each standard curve. The absolute concentrations of total A␤ reported herein are derived by adding the absolute concentrations measured by the two individual A␤ ELISAs: A␤ 1-40 and A␤ .
IP and digestion of sAPP␤. IP of sAPP␤ from CSF was performed using a rabbit monoclonal antibody that can specifically recognize the KMneo-epitope of sAPP␤ created following the cleavage of APP by BACE. The generation and specificity characterization of the prepared antisAPP␤ neo-epitope antibody Mrk-61 was previously described Wu et al., 2012) . Mrk-61 binds exclusively to sAPP␤, and not to sAPP␣, in both Western blot and direct immunoassay experiments that use coated recombinant protein. The purified rabbit monoclonal antiMrk-61 antibody was conjugated with CNBr-activated Sepharose 4B beads (GE Healthcare) according to the manufacturer's protocol. The activity of the Sepharose 4B-conjugated Mrk-61 antibody was evaluated for IP efficiency with normal NHP CSF following overnight bead incubation and the sAPP␤ level in CSF after IP was measured with a sensitive sAPP␤ ELISA . The characterized Mrk-61-Sepharose 4B beads were then reconstituted into a 50% slurry of 0.02% sodium azide in PBS and stored at 4°C.
From each time point, 500 l of CSF, in parallel with a set of H4-APP wt media isotopic enrichment standards (0, 1.25, 2.5, 5, 10, and 20% 13 C 6 -leucine), was diluted 1:1 with 500 l PBS. Protease inhibitors (40 g/ml aprotinin and 20 g/ml leupeptin; Calbiochem/EMD Millipore) were added to each sample at a volume of 10 l, followed by the addition of 50 l of Mrk-61 beads.
Samples were rotated for ϳ22 h at 4°C, then centrifuged (16,837 ϫ g) with 925 l of resulting supernatants collected into new Axygen tubes and stored at 4°C for ϳ1.5 h until ready for the sAPP␣/A␤ immunoprecipitation protocol. The Mrk-61 bead pellets were washed three times with 25 mM ammonium bicarbonate (AmBic), with centrifugation between washes. The supernatants from the bead washes were aspirated after the final rinse and 100 l of neat formic acid was immediately added to each sample to elute the sAPP␤ from the antibody-bead complex. Samples were left for 10 min at 25°C and centrifuged. The formic acid supernatants were transferred to a new Axygen tube and evaporated in a rotary evaporator at 37°C for 30 min. The dried samples were reconstituted with 25 mM AmBic, and 5 ng sequencing-grade metalloendopeptidase (Lys-N; Seikagaku/Associates of Cape Cod) in 25 mM AmBic was added. Extracts were digested for ϳ20 h on a shaker at 37°C and transferred into autosampler vials.
IP and digestion of sAPP␣ and A␤. Before study onset, a mouse monoclonal antibody W0 -2 (EMD Millipore; directed against A␤ 1-10 ) and a mouse monoclonal antibody HJ5.1 (Washington University, St. Louis, MO; directed against A␤ 13-28 ) were covalently bound to CNBr Sepharose 4B beads according to the manufacturer's instructions, then stored in a 50% slurry of 0.02% PBS azide at 4°C before use. The sAPP␣/A␤ IP protocol was optimized for maximum sAPP␣/A␤ signal from the liquid chromatography-mass spectrometer (LC-MS) system. The abovementioned CSF samples and H4-APP wt media APP standard supernatants were taken from 4°C and put on ice. To each sample 45 l W0-2 antibody slurry and 60 l HJ5.1 antibody slurry were added. Samples were rotated, rinsed, eluted, evaporated, reconstituted, and digested using the same methods applied to the Mrk-61 bead eluates.
Quantitation of peptides by LC-MS. Mid-domain APP peptides specific to sAPP␣ and sAPP␤ (KYL(L*)ETPGDENEHAHFQ), and a middomain A␤ peptide (KL(L*)VFFAEDVGSN; Fig. 1 ) were analyzed on a Thermo-Finnigan LTQ (Thermo Fisher Scientific) equipped with nanoflow electrospray ionization (nano-ESI; New Objective) source. The peptides were separated by reverse phase HPLC using a 2D-LC nanoflow pump (Eksigent) operating in 1D mode at a flow rate of 200 nl/min. Sample (5 l) was injected onto a PicoFrit column (New Objective) packed to 12 cm with 5 m Magic C18 aq packing material (Michrom Bioresources). Mobile Phase A contained 0.1% formic acid (FA) in water and Mobile Phase B was 0.1% FA in acetonitrile.
Free leucine quantitation by gas-chromatography-mass spectrometry. Plasma 13 C 6 -leucine/ 12 C 6 -leucine enrichment was determined using gas capillary gas chromatography-mass spectrometry (GC-MS; Agilent 6890N gas chromatograph and Agilent 5973N mass selective detector) in negative chemical ionization mode as described previously (Yarasheski et al., 1992; Bateman et al., 2007; , and 13 C 6 -leucine enrichment was quantified as a relative measure, tracer to tracee ratio ( 13 C 6 -leucine/ 12 C 6 -leucine; Wolfe et al., 2005) . Calculation of labeled APP metabolite ratio. The percentage of labeled metabolite measured using the SILK method was determined by taking the ratio of b-and y-product ion intensities from the unlabeled metabolite peptide and the labeled peptide. For A␤, the peptide quantified was KL(L*)VFFAEDVGSN. For sAPP␣ and sAPP␤, the peptide was KYL(L*)ETPGDENEHAHFQ. Mole fraction label (MFL) was calculated as MFL ϭ L/(L ϩ U ), where L and U are the signal intensities for 13 C 6 -leucine (labeled) peptides and 12 C 6 -leucine (unlabeled) peptides, respectively.
Calculations of fractional synthesis rate and monoexponential slope fractional clearance rate. The fractional synthesis rate (FSR) and monoexponential slope fractional clearance rate (FCR) were quantified for each metabolite as previously reported . Briefly, FSR for each CSF APP metabolite was calculated as the slope of the labeled metabolite during 2-8 h, divided by the average plasma 13 C 6 -leucine enrichment over that time course. The monoexponential slope FCR was computed using the natural logarithm of each labeled metabolite during the clearance phase of the labeled proteins, notably 18 -30 h.
Calculation of newly generated APP metabolites. The concentration of newly generated APP metabolites at each time point was calculated as the product of the absolute concentration of a metabolite (determined by ELISA) and the fraction of the metabolite derived from de novo synthesis, i.e., the percentage of metabolite labeled ( 13 C 6 -leucine-peptide/ 12 C 6 -leucine-peptide ion intensities, established by LC-MS) after normalization to the plasma 13 C 6 -leucine/ 12 C 6 -leucine enrichment, established by GC-MS .
Area under the curve and statistical analyses. For each APP analyte and drug exposure, area under the curve (AUC) was calculated using the trapezoid rule, from Ϫ1 to 57 h (AUC 57 ) for APP analytes and from 0 to 59 h (AUC 59 ) for drug. These time durations were chosen due to the majority of the drug effects and labeling occurring over this period. To estimate the effect of each active treatment versus vehicle, a linear mixed effects model with fixed effects for treatments and random effects for monkeys was fit to the log (base 2) of AUC 57 . Estimates of mean differences from vehicle were back-transformed from the log scale to yield percentage differences. Estimation of the linear relationship between each analyte and drug exposure was performed using a mixed effects model like the one above, except with the treatment effects replaced by a slope and intercept for exposure. Error bars reported in the figures rep- 
Results
Rhesus macaque APP metabolite kinetics sAPP␣ and sAPP␤ turnover was slower than A␤ in the CSF. The average kinetic curves of sAPP␣, sAPP␤, and A␤ in the vehicletreated group were evaluated ( Fig. 2A) , comparing CSF parameters including maximum MFL and time of maximum peak labeling. Soluble APP␣ achieved a maximum of 0.076 Ϯ 0. Kinetic rates of the APP metabolites were estimated using FSR to estimate production rate and monoexponential slope FCR to estimate clearance rate. CSF measures were used throughout as a surrogate for brain rates. FSRs and monoexponential slope FCRs are only valid when measured in a steady-state system (Wolfe et al., 2005) , thus kinetic analyses of sAPP␣, sAPP␤, and A␤ were performed exclusively using data collected from the vehicletreated monkeys. The mean sAPP␣ FSR [3.8 Ϯ 0.4%/h (SD)] was ϳ18% faster than the mean sAPP␤ FSR [3.1 Ϯ 0.5%/h (SD), *p ϭ 0.01; Fig. 2D ]. The mean A␤ FSR was 7.3 Ϯ 0.9%/h (SD; Fig. 2D ) and was slightly lower than the previously reported NHP A␤ FSR (dashed red line) of 10.7 Ϯ 0.6%/h (SEM; . The mean A␤ FSR was 58 and 48% faster than that of either sAPP␤ (***p ϭ 0.0002) or sAPP␣ (***p ϭ 0.0006), respectively.
Mean FCRs for sAPP␣ and sAPP␤ were 7.8 Ϯ 0.7 (SD) and 8.3 Ϯ 1.4%/h (SD), respectively (Fig. 2E) . Mean A␤ FCR was 13.0 Ϯ 1.9%/h (SD; Fig. 2E ) and was slightly faster than the previously reported NHP A␤ FCR (dashed red line) of 9.9 Ϯ 0.5% /h (SEM; , as well as approximately twice as fast as mean human A␤ FCR (dashed black line) previously reported (Bateman et al., 2006) . The FCRs of all three metabolites were significantly different (**p Ͻ 0.002) as assessed by a one-way repeatedmeasures ANOVA. A␤ FCR was significantly faster than FCR of either sAPP␤ (*p Ͻ 0.02) or sAPP␣ (**p Ͻ 0.005), 36 and 40% faster, respectively. The FCRs for sAPP␤ and sAPP␣ were not significantly different from one another (p ϭ 0.6). For each metabolite, the FSR is approximately half of the respective FCR. The discrepancy between each metabolite's FSR and FCR is currently being further evaluated by multicompartmental modeling.
Concentrations of MBI-5 were measured in the plasma (Fig.  3A-C) and CSF ( Fig. 3D-F ) of each subject to determine the inhibitor's PK at each of the three doses. Individual subjects' AUC 59 for MBI-5 in plasma (Fig. 3G ) and in CSF (Fig. 3H ) were determined. The AUC 59 was converted to a log scale and plotted against dosage of MBI-5. Group-averaged AUC 59 for plasma and CSF are plotted against dose in Figure 3I . As expected, MBI-5 levels in both plasma and CSF increased with increasing dose, but a linear effect was seen only in plasma. Individual plasma and CSF AUC 59 C max and T max for each subject at each dose are shown in Tables 2, 3 .
Biological variability of APP product concentrations
Some inherent physiological variability of APP metabolites is expected. For each monkey, three baseline concentrations at t ϭ Ϫ22, Ϫ20, and Ϫ1 h (before leucine infusion and treatment) of sAPP␣, sAPP␤, and A␤ (A␤ 40 ϩ A␤ 42 ) were measured by ELISA in the vehicle group and each of the experimental groups. The means and SDs are reported in Table 4 and indicate a widespread physiological intra-and inter-monkey variability. sAPP␣ and sAPP␤ concentrations were positively correlated (Pearson r ϭ 0.98; **p ϭ 0.004; 95% CI: 0.706 -0.999). However, A␤ concentrations were not correlated to either sAPP␤ (Pearson r ϭ Ϫ0.063; p ϭ 0.92; 95% CI: Ϫ0.895 to 0.868) or sAPP␣ (Pearson r ϭ Ϫ0.098; p ϭ 0.88; 95% CI: Ϫ0.902 to 0.859). With small sample size, high precision is not expected, and this is evidenced by the broad 95% CIs for the correlations involving A␤.
BACE inhibitor dose dependently decreased sAPP␤ and A␤ in NHP CSF
Labeling curves of A␤ (Fig. 4A) and sAPP␤ (Fig. 4D) , as well as absolute concentrations of both analytes measured by ELISA (Fig. 4 B, E) , decreased dose dependently in the presence of a BACE inhibitor. Concentrations of newly generated metabolites were calculated by taking the product of percentage labeled and absolute concentration of a given metabolite at each time point. Similarly to the labeling profiles and absolute concentrations, the newly generated A␤ (Fig. 4C) and sAPP␤ (Fig. 4F ) reflect a dosedependent decrease in the presence of a BACE inhibitor. AUC for A␤ or sAPP␤ labeling for each monkey after each dose of BACE inhibitor were normalized to each monkey's vehicle labeling curve AUC and averaged. Dose-dependent decreases were observed in AUC 57 for A␤ and sAPP␤ when measured by SILK, by ELISA, and in the newly generated peptide calculations (Table 5) .
To determine the relative sensitivity of the assays in this study, we calculated MTSD values for SILK AUC 57 versus ELISA AUC 57 for each metabolite. MTSD was always higher for SILK measurements when compared with ELISA, in all doses and for both metabolites. In the cases of highest dose, SILK was clearly more sensitive for sAPP␤ (*p Ͻ 0.05). The A␤ MTSD was comparable between the two methods used ( p ϭ 0.22).
Mean values from each BACE inhibitor dosage group for each analyte were compared with the mean value of each vehicle group. The MFL A␤ AUC 57 ( 13 C 6 -A␤/ 12 C 6 -A␤) indicated a dose-dependent decrease to ϳ48% of vehicle at the highest BACE inhibitor dose of 125 mg/kg (Fig. 5A, Table 5) ; ϳ10% of the total A␤ is labeled. AUCs for ELISA concentrations of A␤ normalized to vehicle showed a dose-dependent response to ϳ33% of vehicle (Fig. 5B, Table 5 ), a greater extent of reduction than measured by SILK. The newly synthesized A␤ is only ϳ9% at the highest dosage of BACE inhibitor (Fig. 5C, Table 5 ). SILK MFL sAPP␤ AUC 57 indicated a dose-dependent decrease to a lesser extent than A␤: ϳ70% of vehicle values at the highest BACE inhibitor dose (Fig. 5D , Table 5 ), with ϳ8% of the total sAPP␤ being labeled. AUCs for ELISA concentrations of sAPP␤ normalized to vehicle showed a dose-dependent response to ϳ38% of vehicle (Fig. 5E, Table 5 ), a greater extent of reduction than measured by SILK. Similarly to A␤, AUC 57 values for newly synthesized sAPP␤ indicated a dose-dependent decrease to an even greater extent, ϳ18% at the highest inhibitor dose, compared with SILK ( Fig.  5F , Table 5 ). For graphical representation of AUC 57 not normalized to the vehicle, please refer to Figure 6 .
BACE inhibition had no detectable effect on fraction labeled sAPP␣ but dose dependently increased total sAPP␣ concentrations measured by ELISA
The labeling curves of sAPP␣ for vehicle and all three BACE inhibitor groups indicated no significant differences in sAPP␣ fraction label (repeated-measures ANOVA, p ϭ 1.0; Fig. 4G ). SILK MFL sAPP␣ AUC 57 indicated a lack of significant difference among dosage groups (Fig. 5G, Table 5 ). Concentrations measured by sAPP␣ ELISA indicated a dose-dependent increase with BACE inhibition (Fig. 4H ) . AUC 57 for absolute concentrations of sAPP␣ normalized to vehicle indicated a dose-dependent increase to ϳ131% at the highest dose (Fig. 5H, Table 5 ). Finally, the newly generated sAPP␣ (the product of steady-state concentration multiplied by the fraction-labeled sAPP␣), demonstrated dose-dependent increases (35%), but to a lesser degree than the observed sAPP␤ decrease (83%; Figs. 4I, 5I, Table 5 ). Again, to determine the relative sensitivity of the assays in this study, we calculated MTSD values for SILK AUC 57 versus ELISA AUC 57 for sAPP␣. MTSD was always higher for SILK measurements when compared with ELISA in all doses ( p ϭ 0.053). For graphical representation of AUC 57 not normalized to the vehicle, please refer to Figure 6 .
Discussion
To date, kinetic behavior of other APP fragments has not been assessed in NHP, although Dobrowolska et al. (2008) demonstrated total sAPP was metabolized ϳ2-fold slower than A␤ in young, healthy humans. To our knowledge, although some basic APP metabolism has been studied in pulse-chase experiments in various cells lines (Weidemann et al., 1989; Oltersdorf et al., 1990; Busciglio et al., 1993; Perez et al., 1996) , there are no prior studies investigating specific sAPP␣ and sAPP␤ metabolism in vivo. Here, we present common features of sAPP␣ and sAPP␤ metabolism measured in NHP CSF. Metabolism of these sAPP species, relative to NHP A␤ metabolism, was comparable to findings in humans (Bateman et al., 2006; Dobrowolska et al., 2008) where metabolic rates of both APP species were twice as slow as for A␤. This correspondence between sAPP metabolism in both species supports rhesus macaques as an appropriate preclinical model surrogate for human CNS APP processing. The slower turnover rates for these larger APP metabolites when compared with A␤ may be driven by delayed transport out of the brain. In addition to the novel findings of A␤ and sAPP kinetics under steady-state conditions, this is the first report using SILK to evaluate in vivo APP metabolite kinetics following treatment with the BACE inhibitor MBI-5, which is distinct from Merck's BACE inhibitor MK-8931, currently in Phase 3 clinical trials. As expected, there was a notable, dosedependent decrease in A␤ and sAPP␤ in the presence of the BACE inhibitor, indicating the drug hit its intended target. The finding that there was a greater percentage reduction in A␤ compared with sAPP␤ in the presence of the inhibitor was consistent with A␤ having faster kinetics at steady state (Fig.  2 D, E, vehicle-treated group) .
Because of conflicting results in previously reported studies that have examined both sAPP␣ and sAPP␤, it was unclear whether the kinetics of ␣-secretase processing of APP to sAPP␣ would also be altered in the presence of a BACE inhibitor. BACE inhibitors applied in cell culture have sometimes led to apparent shunting of APP down the ␣-secretase pathway resulting in increased sAPP␣ secretion (Hussain et al., 2007; Fukumoto et al., 2010) , but not always (Kim et al., 2008) . This has contrasted with human studies that seemed to indicate a noncompetitive relationship between the ␣-secretase and BACE APP processing pathways (Gabelle et al., 2010; Lewczuk et al., 2010; Alexopolous et al., 2012; Dobrowolska et al., 2014) . Our reported baseline positive correlation of sAPP␣ and sAPP␤ further supports this. Nevertheless, pharmacological intervention may alter normal 
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Concentrations of A␤ and sAPP␤ decreased dose dependently and absolute concentrations of sAPP␣ increased dose dependently with a BACE inhibitor (measured by ELISA). C, F, I, Newly generated A␤ and sAPP␤ decreased dose dependently and newly generated sAPP␣ increased dose dependently with a BACE inhibitor (measured as product of LC-MS labeling and ELISA absolute concentrations at each time point). Error bars indicate SD. APP processing such that decreased BACE activity diverts APP into the ␣-secretase pathway, as demonstrated by May et al. (2011) in humans after BACE1 inhibitor LY2811376 administration resulted in an increase of CSF sAPP␣ corresponding to a decrease of CSF sAPP␤. Our study in NHP suggests that different APP fragment pools can manifest a spectrum of responses as supported by these findings: (1) no apparent change in the MFL sAPP␣ during duration of BACE inhibition used in this study (as well as a smaller degree of AUC changes in sAPP␤ and A␤) and (2) in contrast, the steady-state, absolute concentration of sAPP␣ demonstrated a dose-dependent sAPP␣ concentration increase (as well as a larger degree of AUC changes in sAPP␤ and A␤). One caveat to the ELISA measures is that sAPP␣ did not increase to the same extent that sAPP␤ decreased (respective change from vehicle at 125 mg/kg in AUC 57 , ϩ35% and Ϫ83%), and there was no rebound of sAPP␤ over baseline following the resumption of BACE activity as drug levels declined. Thus, a build-up of APP substrate may be degraded through mechanisms other than traditional ␣-secretase cleavage activities to account for these observations. For example, recent IP studies indicate that alternative ␣-and ␤-secretase processing may occur in vivo in human CNS, i.e., sAPP␣ Q686 (sAPP␣Ј), sAPP␣ K687 , sAPP␤ M671 , and sAPP␤ Y681 (sAPP␤Ј) from the APP 770 splice variant , which might not be detected with our SILK or ELISA assays. Conversely, the additional APP substrate may undergo lysosomal degradation. Measurements using SILK would not reflect APP shunted toward lysosomes, as these fragments would be unlikely to travel to CSF. The MFL profiles of A␤ and sAPP␤ were reduced in a dosedependent manner with increasing doses of BACE inhibitor, concomitant with decreased CSF concentrations of these proteins measured by ELISA. In contrast, the MFL of sAPP␣ was virtually unaltered despite a dose-dependent increase of ϳ30% in the ELISA concentration AUC 57 in the highest dose group (Fig.  5G ,H, Table 5 ). This apparent dichotomy can be explained based on simulations using nonsteady-state compartmental modeling (B.W. Patterson, J. Stone, and E.M.T. van Maanen, unpublished observations). BACE inhibitor was introduced around the same time as 13 C 6 -leucine tracer so the system transitioned from steady state to a nonsteady state as tracer entered the system. We may presume that the production of labeled A␤ and sAPP␤ was almost immediately decreased in a dose-dependent manner as drug reached effective concentrations in the brain. The newly synthesized, 13 C 6 leucine-labeled peptides moved into pools of pre-existing CSF peptides that initially remained near basal absolute concentrations, since turnover of the CSF pools must occur before CSF concentrations decrease in response to BACE inhibition. The decreased appearance of labeled A␤ and sAPP␤ in CSF preceded the decrease in CSF absolute concentration, comprised of an excess of unlabeled peptides, thus resulting in a dosedependent decrease in the labeled to unlabeled peptide ratio (i.e., isotopic enrichment). BACE inhibition should, conversely, cause the amount of APP substrate to increase, leading to increased production of sAPP␣ due to mass action. Thus, increasing amounts of labeled sAPP␣ should appear in CSF dose dependently. The absolute concentration of CSF sAPP␣ will increase concomitant with, and in proportion to, increased appearance of labeled sAPP␣, and thus there would be little impact to the labeled to unlabeled peptide ratio. In addition to the role of CSF turnover on the differential sensitivity of both A␤ and sAPP␤ enrichment profiles to acute inhibition versus an increase of sAPP␣ peptide synthesis, this also resulted in part because peptides were sampled from a downstream location (CSF) remote from the site of BACE activity (brain). 57 were decreased dose dependently, while MFL sAPP␣ AUC 57 indicated that dosing groups did not significantly differ from the vehicle-treated group. B, E, H, AUC 57 values for absolute concentrations of A␤ and sAPP␤ were decreased dose dependently, while AUC 57 of absolute concentrations of three monkeys' sAPP␣ increased. Two monkeys did not show significant changes in sAPP␣. Coincidentally, these two monkeys had the lowest C max for the 125 mg/kg dose among all the monkeys, and were in the lower spectrum for C max at the 30 mg/kg dose. C, F, I, AUC 57 values for newly synthesized A␤ and sAPP␤ were decreased dose dependently, while AUC 57 of newly synthesized of sAPP␣ presented a dose-dependent increase.
Further, of note is that in our study, for each metabolite, its FSR is not equal to its FCR. The FSR and FCR are imperfect indices of true turnover rate that are calculated under the assumption of a single compartmental model. However, there are many compartments in which APP may be processed and trafficked in a complex mammalian organism setting. Thus, the FSR calculations tend to be grossly underestimated and the true FSR is likely much greater than what we report and probably quite similar to our reported FCR, whose calculations are not perturbed by the added complexity of additional compartments. The FSRs and the FCRs reported here are useful in relative comparisons of the three APP metabolites in this study, but a multicompartmental model that fits the full time course could provide a closer estimate of each metabolite's true turnover rate. Such a modeling approach is currently under way.
A detailed mechanism-based, nonsteady-state PK-PD compartmental model (Danhof et al., 2005) is also in progress and will account for both the ELISA concentration data and SILK tracer enrichment time courses of APP metabolites as a function of dynamic BACE inhibition for all doses of BACE inhibitor administered, versus vehicle treatment. The model will also incorporate information from acute inhibition of ␥-secretase activity Van Maanen et al., 2013) .
The current study has the benefit of measuring changes in APP metabolites by two separate methods: using SILK and MS, as well as measuring absolute concentrations by ELISA. SILK is a robust and reliable method of quantifying de novo proteins changing over time following a labeling pulse, whereas the ELISA assays measure the steady-state concentrations of a particular metabolite. SILK is more specific to newly generated proteins and more sensitive to detect changes at earlier time points in a secretase inhibitor setting where protein ELISA variance may mask relatively smaller changes in concentrations. Increased sensitivity of SILK is evidenced by the earlier appearance of the change in the ratio of label versus the ELISA absolute concentration changes. Additionally, SILK AUCs always had higher MTSD values than ELISA AUCs among all dose groups and metabolites.
The CNS kinetic rates of APP metabolites are an important physiologic measure that is tightly regulated and fairly consistent across primates in studies to date. Modulation of APP processing is a key approach in AD therapeutic development with BACE inhibition being an attractive target. This is consistent with recent genetic evidence of a protective factor (Jonsson et al., 2012) in individuals with a mutation at the BACE cleavage site of APP that prevents development of AD. The CNS in vivo study reported here indicates that BACE inhibition modulated APP processing in a predictable and dose-dependent fashion, but the study also provides a novel finding into the balance of BACE and ␣-secretase APP processing following BACE inhibition.
